Weiss Ratings Reiterates Sell (D-) Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “sell (d-)” rating reaffirmed by equities researchers at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

NRXP has been the subject of a number of other research reports. D. Boral Capital reiterated a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, October 21st. BTIG Research reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Monday, August 25th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday, October 16th. Finally, Zacks Research upgraded shares of NRx Pharmaceuticals to a “hold” rating in a research note on Wednesday, September 10th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock opened at $3.15 on Friday. The stock has a market cap of $62.40 million, a P/E ratio of -1.41 and a beta of 1.74. The company has a fifty day moving average price of $2.96 and a two-hundred day moving average price of $2.79. NRx Pharmaceuticals has a one year low of $1.12 and a one year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings results on Monday, August 18th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.67). As a group, equities research analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Ethos Financial Group LLC bought a new position in NRx Pharmaceuticals during the third quarter worth about $39,000. Geode Capital Management LLC increased its position in NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after acquiring an additional 37,598 shares during the period. Finally, Anson Funds Management LP increased its position in NRx Pharmaceuticals by 535.1% during the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after acquiring an additional 993,401 shares during the period. 4.27% of the stock is owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.